化合物Voxtalisib Analogue T1826
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
5 mg | 1349796-36-6 | ¥947.00 | 询底价 |
1 mg | 1349796-36-6 | ¥427.00 | 询底价 |
2 mg | 1349796-36-6 | ¥616.00 | 询底价 |
10 mg | 1349796-36-6 | ¥1,660.00 | 询底价 |
1 mL | 1349796-36-6 | ¥1,290.00 | 询底价 |
500 mg | 1349796-36-6 | ¥12,600.00 | 询底价 |
100 mg | 1349796-36-6 | ¥6,170.00 | 询底价 |
50 mg | 1349796-36-6 | ¥4,330.00 | 询底价 |
25 mg | 1349796-36-6 | ¥2,890.00 | 询底价 |
Product Introduction
Bioactivity
英文名: PI3K-IN-1
描述: PI3K-IN-1 (Voxtalisib Analogue) 是 PI3K 抑制剂,PI3K-IN-1(25 μM) 能够阻断 PI3K/Akt 信号通路。
细胞实验: Cells are treated with XL765 24 hours after plating and harvested for apoptosis or autophagy assays at 24, 48, or 72 hours after XL765 treatment. Apoptosis is determined by total percentage of annexin V-positive cells by fluorescence-activated cell sorting (FACS). Acidic vesicular organelles (AVOs) are detected in XL765-treated cells by vital staining with acridine orange. The degree of AVO formation is expressed as fold increase of acridine orange fluorescence intensity (FL3) in XL765-treated cells versus control cells. (Only for Reference)
激酶实验: Radioligand Binding Assays: Each tube in the A3 AR competitive binding assay contains 100 μL of membrane suspension (20 μg of protein), 50 μL of [125I]4-amino-3-iodobenzyl)adenosine-5′-N-methyluronamide (0.5 nM), and 50 μL of increasing concentrations of the test ligands in Tris-HCl buffer (50 mM, pH 7.4) containing 10 mM MgCl2 and 1 mM EDTA. Nonspecific binding is determined using 10 mM 5′-N-ethylcarboxamidoadenosine in the buffer. The mixtures are incubated at 25°C for 60 min. Binding reactions are terminated by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester. Filters are washed three times with 9 mL of ice-cold buffer. Radioactivity is determined using a Beckman γ-counter, and the percent inhibition is calculated.
体外活性: 在GBM 39-luc细胞植入的裸鼠中,口服XL765能够抑制肿瘤细胞的生长,同时提高存活率.在BxPC-3异种移植物小鼠模型中,XL765(30 mg / kg)与氯喹(50 mg / kg)联用,能够抑制肿瘤细胞生长.
体内活性: XL765对于I类PI3K有抑制作用,对于对于p110α(IC50=39 nM),p110β(IC50=113 nM),p110γ(IC50=9 nM)和p110δ(IC50=43 nM)。XL765通过显着抑制mTOR靶点S6,S6K和4EBP1的磷酸化,对mTOR(IC50 = 157 nM)产生抑制作用。在MIAPaCa-2细胞中,XL765处理后,产生自噬体积累。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 10 mg/mL (16.7 mM)
H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字: Phosphoinositide 3-kinase | muscle | XL-147 derivative 1 | cancer | PI-3K-IN-1 | SRC | SAR 245409 | PI3K | XL-765 | fibrosis | inhibit | extraocular | thyroid | PI3K IN 1 | Inhibitor | PI3K-IN-1 | SAR-245409 | ophthalmopathy | XL 765 | PI3KIN1 | gene
相关产品: (Rac)-Nedisertib | CC-115 | KU-57788 | Pictilisib dimethanesulfonate | PIK-93 | PIK-75 hydrochloride | PIK-90 | (R)-(-)-Rolipram | Onatasertib | ETP-46464
相关库: Drug Repurposing Compound Library | HIF-1 Signaling Pathway Compound Library | Anti-Cancer Drug Library | Clinical Compound Library | Anti-Metabolism Disease Compound Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Kinase Inhibitor Library | Anti-Cancer Active Compound Library | Stem Cell Differentiation Compound Library
化合物Voxtalisib Analogue T1826信息由TargetMol中国为您提供,如您想了解更多关于化合物Voxtalisib Analogue T1826报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途